Roundtable Discussion: Engaging the FDA Proactively to Access Tailored Regulatory Guidance & Accelerate Microbiome Therapeutic Development
- Addressing common misconceptions about FDA regulatory support availability to help microbiome companies access existing flexible guidance frameworks suited to complex biological products
- Implementing proactive FDA engagement strategies including early pre-IND/BLA meetings and ongoing dialogue to secure product-specific guidance and prevent costly late-stage regulatory surprises
- Sharing company experiences navigating FDA interactions to build collective understanding of how tailored regulatory conversations accelerate development timelines for diverse microbiome therapeutic modalities